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TP53 is the most frequently mutated gene in cancer. The p53 protein activates transcrip-
tion of genes that promote cell cycle arrest or apoptosis, or regulate cell metabolism, 
and other processes. Missense mutations in TP53 abolish specific DNA binding of p53 
and allow evasion of apoptosis and accelerated tumor progression. Mutant p53 often 
accumulates at high levels in tumor cells. Pharmacological reactivation of mutant p53 
has emerged as a promising strategy for improved cancer therapy. Small molecules that 
restore wild type activity of mutant p53 have been identified using various approaches. 
One of these molecules, APR-246, is a prodrug that is converted to the Michael accep-
tor methylene quinuclidinone (MQ) that binds covalently to cysteines in p53, leading to 
refolding and restoration of wild type p53 function. MQ also targets the cellular redox 
balance by inhibiting thioredoxin reductase (TrxR1) and depleting glutathione. This dual 
mechanism of action may account for the striking synergy between APR-246 and 
platinum compounds. APR-246 is the only mutant p53-targeting compound in clinical 
development. A phase I/IIa clinical trial in hematological malignancies and prostate can-
cer showed good safety profile and clinical effects in some patients. APR-246 is currently 
tested in a phase Ib/II trial in patients with high-grade serous ovarian cancer.
Keywords: APR-246, mutant p53, apoptosis, thioredoxin reductase, glutathione, redox balance, clinical trial, 
cancer therapy
iNTRODUCTiON
Recent DNA sequencing of 3281 human tumors within The Cancer Genome Atlas (TCGA) has 
confirmed the high frequency of TP53 mutations in cancer. At least 42% of the cases of 12 common 
human tumor types carry mutant TP53 (1). In high-grade serous (HGS) ovarian cancer, the fraction 
of tumors with mutant TP53 is almost 95%. No other gene is mutated at such high frequency in 
cancer. See also TP53 databases p53.iarc.fr and p53.free.fr. The second and third most frequently 
mutated genes are PIK3CA that encodes the p110 alpha catalytic subunit of PI3 kinase and PTEN, 
a lipid phosphatase that regulates Akt kinase activation, which are mutated in 17.8 and 9.7% of the 
cases of the 12 common tumor types, respectively (1).
Wild type p53 protein induces cell cycle arrest, senescence, and apoptosis in response to cellular 
stress by upregulating target genes such as p21, Bax, Puma, and Noxa (2). p53 can also regulate cell 
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metabolism and redox status through target genes such as TIGAR 
and GLS2 (3–5). It remains unclear exactly how p53 mediates 
potent tumor suppression. In vivo studies in mice have shown that 
certain engineered p53 mutants that fail to transactivate pro-arrest 
and pro-apoptosis target genes can still prevent tumor develop-
ment (6, 7). Similarly, mice lacking the p53 target genes p21 that 
mediates p53-dependent cell cycle arrest and Puma and Noxa that 
mediate p53-dependent apoptosis do not show increased tumor 
incidence (8). These findings argue that other p53 transcriptional 
targets, for instance those involved in regulation of metabolism, 
are critical for p53-mediated tumor suppression.
Oncogenic stress as a result of oncogene activation or loss of 
cell cycle control characterizes early stages of tumor evolution. 
This leads to aberrant DNA replication, which triggers a DNA 
damage response (DDR) involving activation of ATM, Chk1 and 
Chk2 kinases, and p53, and induction of senescence or apoptosis 
(9). Activation of DDR and p53 upon oncogenic stress serves 
to eliminate incipient tumor cells and forms a critical barrier 
against tumor development. DDR inactivation by mutation in 
ATM or TP53 allows cell survival and tumor progression. Many 
TP53 mutations are missense mutations resulting in amino acid 
substitutions in the DNA-binding core domain and disruption 
of p53-specific DNA binding and transcriptional transactivation 
(10). Loss of wild type p53 is associated with increased resistance 
to chemotherapy.
The high frequency of missense TP53 mutations in human 
tumors and the fact that mutant p53 often accumulates at high 
levels in tumor cells make mutant p53 a potential target for 
improved cancer therapy. Pharmacological reactivation of mutant 
p53 would restore p53-dependent senescence and apoptosis, and 
presumably also p53-mediated regulation of metabolism and 
other processes, and thus eliminate tumors in vivo. Indeed, studies 
in various mouse models have demonstrated that restoration of 
wild type p53 expression in vivo leads to rapid tumor elimination 
(11–13). This suggests that restoration of functional p53 can trig-
ger tumor cell death and lead to tumor clearance even if a tumor 
carries multiple genetic alterations that drive tumor growth.
PHARMACOLOGiCAL ReACTivATiON OF 
MUTANT p53
A growing number of small molecules that can reactivate 
mutant p53 have been identified over the past 15  years, using 
either chemical library screening or rational drug design. These 
include CP31398, PRIMA-1Met/APR-246, PK-083, PK-5174, 
SCH529074, and NSC319726 (ZMC1). We have previously 
reviewed this field (14). This review is focused on PRIMA-1 
(APR-017) and the structural analog PRIMA-1Met, now named 
APR-246, both of which were identified in our laboratory. As will 
be discussed below, both compounds are prodrugs that form the 
active moiety MQ. We will also highlight the clinical development 
of APR-246.
We identified PRIMA-1 in a screen of a small structur-
ally diversified chemical library from NCI (Diversity set) for 
compounds that could induce cell cycle arrest or cell death 
preferentially in cells expressing mutant p53 (15). Cell growth 
and viability were assessed by the WST1 assay. PRIMA-1 showed 
the strongest preference for mutant p53-expressing cells and was 
selected for further studies. Experiments with antibodies specific 
for correctly folded wild type p53 (PAb1620) or unfolded mutant 
p53 (PAb240) revealed that PRIMA-1 could induce refolding of 
mutant p53 and enhance mutant p53 DNA binding in gel shift 
assays. PRIMA-1 treatment of tumor cells carrying various 
mutant p53 resulted in upregulation of p53 target genes such as 
p21, Bax, and Mdm2, and induction of cell death by apoptosis. 
Systemic administration of PRIMA-1 in mice carrying Saos-2-
His273 tumor xenografts demonstrated significant inhibition 
of xenograft tumor growth in vivo (15). In parallel, our analysis 
of available data in the NCI database confirmed that PRIMA-1 
preferentially targets tumors cells carrying mutant p53 and has 
an activity profile that is entirely distinct from those of commonly 
used chemotherapeutic drugs such as cisplatin and 5-FU (16). 
Subsequently, the structural analog PRIMA-1Met or APR-246 
that has superior permeability properties was identified. APR-
246 was shown to synergize with chemotherapeutic drugs, e.g., 
adriamycin and cisplatin (17).
TARGeTiNG MUTANT p53 BY MiCHAeL 
ADDiTiON
Our data clearly showed that PRIMA-1 and APR-246 were able 
to reactivate various forms of mutant p53 and trigger tumor cell 
apoptosis, but their molecular mechanism of action remained 
obscure. However, we found that both compounds are con-
verted to methylene quinuclidinone, MQ, a Michael acceptor 
that can react with soft nucleophiles such as thiols in proteins 
(Figure 1). The p53 core domain has 10 cysteine residues. Mass 
spectrometry demonstrated that MQ binds covalently to the p53 
core domain (18). Several findings support the notion that MQ 
binding to p53 is critical for the effect of PRIMA-1 and APR-246. 
N-acetylcysteine (NAC), a thiol group donor, blocks PRIMA-1-
induced apoptosis and PRIMA-D (APR-320), a structural analog 
that cannot be converted to MQ, has no effect on tumor cells 
at concentrations corresponding to those used for PRIMA-1 
and APR-246. Moreover, transfer of MQ-modified mutant p53 
protein into p53 null tumor cells induces expression of p53 target 
genes and cell death by apoptosis (18). These results demonstrate 
that MQ is the active compound and that MQ-modification of 
mutant p53 per se is sufficient to induce tumor cell death. Thus, 
PRIMA-1 and APR-246 are prodrugs that form the biologically 
active compound MQ (Figure 1). This conversion is spontane-
ous and occurs over a time frame of a few hours at physiological 
pH (18). Since MQ is reactive, its administration as a prodrug is 
probably critical in order to avoid adduct formation with various 
extracellular targets.
It is interesting to note that MIRA-1, another compound 
identified in our screen of the NCI Diversity set, is a maleimide 
with known Michael acceptor activity. Moreover, Kaar and Fersht 
and their colleagues identified a series of Michael acceptors that 
bind covalently to both wild type and mutant p53 core domains, 
resulting in increased protein melting temperature. Analysis 
of the reactivity of the cysteines in p53 by mass spectrometry 
FiGURe 1 | Chemical structures of PRiMA-1 and APR-246 (PRiMA-
1Met). Both compounds form the Michael acceptor methylene 
quinuclidinone (MQ), which is the active moiety. MQ binds covalently to thiols 
in mutant p53. MQ also targets thioredoxin reductase (TrxR) and glutathione 
(GSH). MQ binding to TrxR converts the enzyme to an active oxidase, which 
generates ROS, and MQ binding to glutathione depletes intracellular free 
glutathione, which also induces ROS.
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revealed preferential reaction with C124 and C141, followed 
by C135, C182, and C277, and then C176 and C275 (19). These 
results further support the idea that adduct formation at cysteines 
can stabilize the native conformation of p53.
Among the 10 cysteine residues in p53’s core domain, 
four – Cys182, Cys229, Cys242, and Cys277 – are exposed on the 
surface of the protein and accessible for modification in correctly 
folded p53 (20, 21). Presumably, additional cysteines are exposed 
in unfolded mutant (or wild type) p53, allowing more extensive 
thiol modification (18). Computational analysis of structural 
p53 models identified a binding pocket between the L1 loop 
and S3 sheet in the p53 core domain, containing cysteines C124, 
C135, and C141 (22). Docking analysis indicated that MQ, as 
well as other thiol-targeting compounds including MIRA-1, can 
bind to the L1/S3 pocket. These results were validated in living 
cells by introduction of a C124A substitution in R175H mutant 
p53. Indeed, C124A substitution abolished the apoptotic effect 
of PRIMA-1 in Saos-2 osteosarcoma cells expressing R175H 
mutant p53.
Thus, APR-246/MQ, MIRA-1 and the compounds identified by 
Kaar et al. (19) share a common chemical property and presum-
ably promote refolding of mutant p53 by a similar mechanism. 
The ability to modify cysteines in mutant p53 distinguishes APR-
246/MQ from compounds like PK-083 and PK-7088 that bind to 
a crevice in the Y220C mutant p53 protein and raise its melting 
temperature (23). APR-246 also has a different mechanism of 
action than the compound NSC319726 (ZMC1), a zinc chelator 
that refolds His175 mutant p53 as well as several other mutant 
p53 proteins (24). Clearly, mutant p53 refolding and reactivation 
can be achieved by various molecular strategies. Some strategies 
work for specific mutant forms of p53, whereas other strategies 
are applicable to a range of mutant p53 proteins.
APR-246 ReACTivATeS MUTANT FORMS 
OF p53 FAMiLY MeMBeRS p63 AND p73
p53 is a member of a protein family with two other members, 
p63 and p73 (25). In contrast to TP53, neither the TP63 nor 
TP73 genes are mutated at any significant frequency in human 
tumors. However, TP63 missense mutations occur in certain 
developmental syndromes such as the Ectrodactyly–ectodermal 
dysplasia–cleft (EEC) syndrome (26). All three proteins share 
a high degree of sequence similarity in the DNA-binding core 
domain (25). The 10 cysteines in the p53 core domain are all 
conserved in both p63 and p73. This raises the question as to 
whether APR-246 can affect mutant p63 and/or p73 folding and 
activity. We first examined the effect of APR-246 on human tumor 
cells carrying exogenous temperature-sensitive missense mutant 
TP63 and TP73. APR-246 induced the expression of p53/p63/p73 
target genes, cell cycle arrest, and cell death by apoptosis in these 
cells (27). To assess the effect of APR-246 on mutant p63 in a more 
physiological context, we used human keratinocytes derived from 
EEC patients carrying R204W or R304W mutant TP63. These 
two TP63 mutants correspond to the tumor-associated hot spot 
TP53 R175H and R273H mutants. Treatment with APR-246 led 
to increased expression of p63 target genes and at least a partial 
rescue of keratinocyte differentiation (28). Similarly, APR-246 
rescued corneal differentiation in iPS cells from EEC individuals 
(29). Thus, the targeting of mutant versions of the two structurally 
related transcription factors p63 and p73 by APR-246 leads to 
entirely different biological responses that recapitulate the normal 
functions of each protein. These results argue convincingly that 
the biological effects of APR-246 are mediated by direct binding 
to mutant p53 or p63 and refolding the mutant proteins into an 
active conformation.
APR-246/MQ TARGeTS COMPONeNTS OF 
THe CeLLULAR ReDOX SYSTeM
The observation that MQ can bind to thiols suggested that it might 
also target thiol-containing redox regulators such as glutathione 
and thioredoxin. Indeed, we found that APR-246 is a potent 
inhibitor of thioredoxin reductase (TrxR1), a selenocysteine-
containing enzyme that catalyzes the reduction of thioredoxin 
(30). APR-246 inhibits the activity of TrxR1 both in vitro and in 
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living cells. This effect is presumably mediated through modifica-
tion of the selenocysteine residue in TrxR1 by MQ. MQ binding 
converts TrxR1 into an NADPH oxidase that contributes to ROS 
production and cell death induced by APR-246 (30).
Methylene quinuclidinone has also been shown to bind to 
cysteines in glutathione (GSH), leading to a decrease in free intra-
cellular glutathione concentrations and increased ROS levels (31, 
32). Since glutathione can mediate resistance to platinum drugs 
by conjugation and export, this effect of MQ may at least in part 
account for the strong synergy between APR-246 and platinum 
drugs (see below). APR-246 did not inhibit GCLM (regulatory 
subunit of γ-glutamyl cysteine-synthase) or GSS (glutathione 
synthetase) in the GSH synthesis pathway, indicating that the 
observed GSH depletion is not caused by decreased synthesis 
(32).
Thus, accumulating data on the effects of PRIMA-1/APR-246 
on the cellular redox balance demonstrate that these compounds 
have a dual mechanism of action that targets two Achille’s heels 
of tumor cells: mutant p53 and the redox balance (Figure  2). 
The targeting of these two pathways may allow more efficient 
elimination of tumor cells and lower the probability of resistance 
development. This dual mechanism provides an explanation for 
reported mutant p53-independent effects of APR-246.
eFFeCTS ON MUTANT AND  
wiLD TYPe p53
Methylene quinuclidinone can bind to both wild type and mutant 
p53 (18), and it is conceivable that MQ binding can induce 
refolding of misfolded wild type p53 in tumor cells. However, 
available data so far indicate that APR-246/MQ has little toxicity 
in normal cells. Wild type p53 is expressed at low levels in most 
normal cells and tissues in the absence of stress, whereas many 
tumor cells express high levels of unfolded mutant p53. Also, 
normal cells have a higher capacity to cope with oxidative stress 
as compared to tumor cells (33). While MQ binding to mutant 
p53 can restore p53-dependent apoptosis (18), MQ binding to 
other cellular proteins may not necessarily have major effects 
on cell growth and survival, except for binding to TrxR and 
GSH and possibly other anti-oxidative proteins, as discussed 
above. The benign safety profile of APR-246 observed in the first 
clinical study (34) is consistent with the lack of major toxicity in 
normal cells.
Interestingly, the response of wild type and mutant TP53-
carrying tumor cells to MQ is enhanced by hypoxia (35). Hypoxia 
(≤1% oxygen) increased the sensitivity of SKBR3 cells (R175H 
mutant TP53) to PRIMA-1 treatment. In MCF-7 cells (wild type 
TP53), chemical hypoxia induced by CoCl2 led to accumulation 
of unfolded wild type p53, as assessed with the monoclonal anti-
body PAb240, and enhanced sensitivity to PRIMA-1. Presumably, 
this is due to MQ binding and refolding of unfolded “mutant-
like” wild type p53 into an active conformation. The finding that 
hypoxia can potentiate the efficacy of PRIMA-1 has important 
clinical implications. Due to insufficient blood supply, rapidly 
growing tumors in vivo are often hypoxic, and it is conceivable 
that this could enhance the therapeutic efficacy of APR-246, both 
in wild type and mutant TP53-carrying tumors.
SYNeRGY wiTH CONveNTiONAL 
CHeMOTHeRAPeUTiC DRUGS AND 
NOveL eXPeRiMeNTAL DRUGS
A major hurdle for achieving efficient elimination of tumors 
and long-term cancer cure is the rapid development of therapy 
resistance. There are numerous mechanisms for such resist-
ance, including enhanced DNA repair and increased efflux of 
chemotherapeutic drugs from the tumor cell (36). The problem 
of resistance is relevant not only for conventional chemo-
therapeutic drugs but also for targeted drugs, as exemplified by 
resistance development in CML upon treatment with the novel 
drug imatinib (Gleevec) that inhibits the BCR-ABL kinase (37). 
Therefore, it is important to explore possible synergies between 
APR-246 and conventional anticancer agents, novel targeted 
drugs, and experimental drugs.
The DNA damage caused by chemotherapeutic drugs such 
as cisplatin and doxorubicin induces tumor cell death to a large 
extent via wild type p53 activation and p53-induced apoptosis. 
Accordingly, tumor cells carrying mutant p53 or completely 
lacking p53 are often more resistant to conventional chemo-
therapy. This suggests that restoration of wild type p53 function 
by APR-246 might synergize with, for example, cisplatin. Indeed, 
we and others have demonstrated strong synergy between APR-
246 and chemotherapeutic drugs such as cisplatin, 5-fluorouracil 
(5-FU), and doxorubicin in mutant p53-carrying lung, ovarian, 
and esophageal cancer cells (17, 31, 38, 39). Synergistic effects 
have also been observed in vivo upon systemic administration 
(17, 39).
There are several possible reasons for the observed synergy 
(Figure  2). First, as alluded to above, restoration of wild type 
function to mutant p53 by APR-246 might increase sensitivity 
to chemotherapeutic drugs that depend on wild type p53 for 
induction of efficient tumor cell apoptosis. Second, treatment 
with cisplatin, adriamycin, or 5-FU leads to accumulation of 
mutant p53 (17, 39), which is expected to enhance the effect of 
APR-246. Third, we and others found that APR-246, via MQ, 
depletes intracellular GSH levels (31, 32). Since formation of 
adducts with GSH and extracellular export is one mechanism 
of cisplatin resistance, MQ-mediated GSH depletion is likely to 
sensitize tumor cells to cisplatin. Fourth, MQ-mediated inhibi-
tion of TrxR and conversion of the enzyme to an active oxidase 
(30) should induce ROS levels, which will further enhance DNA 
damage and p53-dependent cell death. Inhibition of TrxR will 
also negatively affect the activity of ribonucleotide reductase, 
needed for providing deoxyribonucleotides for DNA replication 
and repair (40).
In contrast to the mutant p53-dependent synergy of APR-246 
with cisplatin and 5-FU, the synergy between APP-246 and epiru-
bicin was p53-independent in esophageal cancer cells (39). This 
could be due to the redox effects of APR-246, including inhibi-
tion of TrxR and/or GSH depletion. Cisplatin and 5-FU, but not 
epirubicin, induced the expression of mutant p53 (39). Synergy 
has also been observed between APR-246 and the experimental 
compound RITA in AML cells. This synergy could arise from 
increased levels of mutant p53 upon induction of DNA damage 
by RITA (41).
FiGURe 2 | APR-246/MQ targets both mutant p53 and the cellular redox balance. The striking synergy between APR-246 and DNA-damaging 
chemotherapeutic drugs such as cisplatin and doxorubicin can be due to (1) refolding and reactivation of mutant p53 by APR-246, which enhances the response to 
DNA-damaging agents; (2) accumulation of mutant p53 by DNA-damaging agents, which potentiates the effect of APR-246; (3) depletion of glutathione by MQ, 
which inhibits efflux of drugs such as cisplatin; and (4) inhibition of TrxR and conversion of the enzyme to an active oxidase, leading to increased oxidative stress.
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In addition, APR-246 synergized with daunorubicin in AML 
cells carrying wild type p53 (41). Synergy in the absence of mutant 
p53 may be due to APR-246-mediated redox effects. However, as 
discussed above, MQ can also bind to wild type p53 and restore 
an active conformation under hypoxic conditions. There is evi-
dence suggesting that wild type p53 may occur in a misfolded 
conformation in some tumors, e.g., B-CLL (42) and AML (43). 
This raises the possibility that refolding of wild type p53 by 
APR-246 may be responsible for synergy with chemotherapeutic 
agents in AML cells.
PRIMA-1 at 50 μM induced G2/M phase accumulation of 
parental mouse L1210 leukemia cells carrying mutant p53 but 
had only a minor effect on the cell cycle distribution of Y8 
cells, a subline of L1210 that lacks p53. A striking synergistic 
induction of necrosis was observed in L1210 cells upon com-
bination treatment with PRIMA-1 and the cyclin-dependent 
kinase inhibitor flavopiridol. However, in Y8 p53 null cells, 
combination of PRIMA-1 and flavopiridol caused a synergistic 
increase in apoptosis (44). Thus, combination treatment with 
PRIMA-1 (or presumably APR-246) can lead to cell death 
through alternative routes, depending on the presence or 
absence of mutant p53.
Mutant p53 reactivation by APR-246 leads to induction of 
the p53 target and antagonist Mdm2 (15), which promotes p53 
degradation by the proteasome. Therefore, it is conceivable that 
inhibition of Mdm2-p53 binding and Mdm2-mediated p53 deg-
radation might potentiate the effect of APR-246. Indeed, strong 
synergy was observed between PRIMA-1 and the Mdm2 inhibitor 
Nutlin-3 in pancreatic cancer cells (45). Moreover, gene therapy 
with the tumor suppressor gene FHIT (fragile histidine triad), 
whose gene product has been shown to inactivate Mdm2 (46), 
resulted in synergistic inhibition of tumor growth in combination 
with APR-246 (47). Since several compounds that disrupt p53-
Mdm2 binding are now being tested in the clinic, these results 
may have profound implications for the future clinical use of both 
APR-246 and inhibitors of p53-Mdm2 binding.
CLiNiCAL DeveLOPMeNT
APR-246 has been tested in a first-in-man phase I/IIa clinical 
trial in patients with hematological malignancies or hormone-
refractory prostate cancer (34). The main aim was to determine 
maximum tolerated dose (MTD) of APR-246 and to assess safety 
and pharmacokinetic properties. Patients were not preselected 
based on TP53 mutation status. The treatment regimen was 
2-h infusion of APR-246 for 4 days. Overall, the study showed 
that APR-246 is well tolerated and only relatively minor and 
transient side effects were observed, including dizziness, fatigue, 
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headache, nausea, and confusion. MTD was defined as 60 mg/
kg. Plasma concentrations of APR-246 reached 250  μM, well 
above concentrations required for robust induction of tumor cell 
apoptosis in cell culture experiments. Analysis of isolated patient 
leukemic cells by FACS revealed induction of p53 targets Bax and 
Puma upon APR-246 treatment, and microarray analysis showed 
substantial alterations in gene expression, including genes associ-
ated with cell cycle regulation and cell death, consistent with the 
proposed mechanism of action. Furthermore, one AML patient 
carrying V173M mutant TP53 showed a significant reduction in 
bone marrow blasts, and one patient with a TP53 splice site muta-
tion had a minor response according to CT scan. Thus, APR-246 
is safe and shows signs of clinical activity. APR-246 is currently 
being tested in combination with carboplatin and pegylated 
doxorubicin in a phase Ib/II clinical study in HGS ovarian cancer, 
a tumor type with a 95% frequency of TP53 mutations (see www.
clinicaltrials.gov).
FUTURe PeRSPeCTiveS
The development of efficient mutant p53-reactivating anticancer 
drugs is expected to have a major impact on public health glob-
ally, given the high frequency of TP53 mutations in a wide range 
of human tumors. In certain tumor types, TP53 is mutated in the 
great majority of the cases. In general, clinical studies have shown 
that mutant TP53-carrying tumors respond less well to conven-
tional chemotherapeutic drugs and have worse prognosis than 
wild type TP53-carrying tumors. The ongoing phase Ib/II clinical 
study with APR-246 will provide solid data on clinical efficacy 
in combination with standard chemotherapy. Importantly, the 
mechanism of action of APR-246  –  i.e., dual targeting of both 
mutant p53 and the cellular redox system – suggests that APR-
246 will synergize with many DNA-damaging chemotherapeutic 
drugs, and such synergy has been confirmed in a number of pub-
lished studies. An important goal for further studies is to assess 
clinical efficacy in combination with relevant chemotherapeutic 
and targeted drugs in various tumor types. Ultimately, APR-246 
may allow greatly improved therapy of a wide range of tumors 
that carry mutant TP53.
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